One month after world leaders went on to make a commitment to increase efforts when it comes to universal health coverage- UHC at the UNGC, representatives from across 70 countries gathered to discuss and enhance expenditures in primary health care by this decade-end.

The International Conference concerning Primary Health Care Policy and Practise- Implementing for Better Results commemorated the 45th anniversary of the Declaration of Alma-Ata as well as the 5th anniversary of the Declaration of Astana on primary health care. The conference took place in Kazakhstan, the birthplace of the historic primary health care declarations. It went on to bring together more than 600 health policy-makers and partners from various countries. The event was co-organized by the Government of Kazakhstan, the World Health Organisation (WHO), as well as UNICEF.

It is well to be noted that vital health services are still not accessible to more than half of the global population. Healthcare costs are causing severe monetary problems for two billion people. The participants emphasised the need for greater expenditures on primary health care. They also highlighted the importance of leveraging technological advances so as to improve healthcare services. Additionally, they stressed the importance of protecting individuals from too many out-of-pocket health expenses. Lastly, they emphasised the need to invest in the healthcare and medical workforce in order to address the anticipated shortage of 10 million health workers by 2030.

During the global epidemic, it has become obvious that those who happen to be economically disadvantaged, the most susceptible individuals, and those who are marginalised are bearing the brunt of the consequences. WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, emphasised that equity should not and can’t be delayed. The WHO, according to him, is dedicated to collaborating with governments, international financing organisations, partners, youth, and civil society in order to bring about an important change in this direction. This will be achieved by placing the focus on taking action and making investments within a primary health care strategy.

In order to globally expand the primary healthcare- PHC approach across low-and-middle-income countries and at the same time fulfil the objectives outlined in the second United Nations Political Declaration on Universal Health  Coverage- UHC adopted on October 5, 2023, a further commitment of a minimum of US$ 200–328 billion in a year is necessary. This amount represents approximately 3.3% of the national gross domestic product.

Notably, the PHC system makes sure that essential health services are of good quality, more affordable, and are also readily available to everyone in a balanced manner. The most equitable, effective, and efficient path to achieving UHC is by way of adopting this approach. The successful implementation of PHC makes it compulsory for strengthened collaboration to enhance political dedication, administration, funding, as well as engagement. It also requires  a shift in perspective, moving away from constructing health systems that solely address diseases and more so fostering the development of systems that prioritise the overall health and well-being of people. This approach aims to bring about healthier communities that are better equipped to safeguard against diseases and and combat them effectively.

Scaling up PHC in countries has the potential to save more than 60 million lives. Additionally, it has the capability to provide 75% of the anticipated health benefits outlined in the Sustainable Development Goals.

WHO’s operations in primary health care

The aim of the WHO Special Programme on Primary Health Care is to help countries in refocusing their health systems onto primary health care. The programme also aims to provide strong standards of practice so as to monitor progress, guarantee ownership, and achieve meaningful impact. The WHO-UHC Partnership plays a critical role in the execution of this work. It consists of over 150 health policy advisers based in 125 countries, as well as 6 WHO regional offices, and is the WHO’s largest platform for international collaboration on UHC. On October 22, 2023, the UHC Partnership hosted a pre-conference workshop that was attended by more than 250 delegates across ministries of health, partners in development, and WHO country offices from various countries around the globe. The workshop helps countries a chance to explore the relationship between primary health care as well as universal health coverage, and also political dynamics involved in health system reforms. It also highlighted the key factors that help with successful innovation and investment in primary health care, with the objective of improving application in the years to come.

The Primary Health Care Accelerator, which happens to be a part of the Global Action Plan for Healthy Lives and Well-Being, happens to be a united effort between WHO, UNICEF, and other partners. The goal of this programme is to help upgrade the support for countries in fulfilling their commitments to universal health coverage by strengthening primary health care. This initiative promotes cooperation as well as coordination across different sectors so as to achieve better outcomes. WHO and also UNICEF have been longstanding partners in the field of primary health care for some time now. The Operational Framework for Primary Health Care has been jointly developed by WHO as well as UNICEF and serves as a complete guide for countries worldwide, offering clear direction when it comes to terms of effective action that needs to be taken.

The European Commission has gone on to take steps so as to tackle the issue of critical medicine shortages. These actions include putting up a unified strategy when it comes to stockpiling drugs and establishing a shortage alert system throughout the European Union. The aim is to prevent a recurrence of the situation that one went through in 2022.

According to a press release from the Commission dated October 24, a Communication went on to be published with the aim of preventing and mitigating critical medicine shortages at the EU level. The Communication is intended to address the issue not just for this winter but also for future winters.

During one of the recent press briefings, Stella Kyriakides, Health Commissioner, expressed her commitment to implementing collective actions when it came to the EU level. These actions aim to enhance the well-being of citizens for the medium and long term and not just the upcoming winter.

Kyriakides went on to express her disbelief at the current situation in Europe in 2023. She stressed that it is unacceptable for patients to be deprived of the necessary medications, particularly with regard to the efforts being made to set up a health union.

It is well to be noted that during last winter, many Europeans faced a harsh reality that was previously unthinkable. They had to deal with a surge of respiratory viruses along with ongoing COVID-19 infections. Additionally, there were challenges such as limited manufacturing capacity, a lack of raw materials, distribution issues, labour delays, and even natural disasters.

Kyriakides stated that medicine shortages cannot be resolved right away due to their long-standing and multifactorial causes.

In order to avoid a similar situation, the Commission has now put forth a proposal in terms of an operational response. This is needed because the actions outlined in the drug strategy cannot be implemented at the moment, as the dossier is still being reviewed by the Council and Parliament.

What does the communication consist of?

The proposed response from the Commission incorporates various aspects of pharmaceutical reform. These include asking companies to provide earlier notification of shortages, implementing shortage mitigation strategies for all medicines, and enhancing the sharing of information when it comes to shortages at the EU level.

The actions include the implementation of a European Voluntary Solidarity Mechanism for medicines, the establishment of a comprehensive list of critical medicines, the implementation of regulatory flexibilities, as well as the provision of EU guidance on purchasing.

The European Voluntary Solidarity Mechanism for Medicines has been established to promptly assist countries that experience shortages by allowing them to request support from countries that have an adequate supply.

Efforts to establish a comprehensive list of critical medicines, consisting of 100 to 350 essential medications, will be expedited. The aim is to offer an initial list by the end of this year. By April 2024, one will have analysed the supply chains of specific drugs and identified measures so as to address any shortages.

The Commission will develop a common strategic approach to medicines accumulating in the first half of 2024. This approach aims to avoid and minimise shortages in collaboration with member states.

Furthermore, the Commission plans to establish a Critical Medicines Alliance, which is expected to be working by early 2024. This initiative is referred to as an industrial policy pillar of the European Health Union.

Kyriakides stated that this alliance is an innovative approach for public authorities in the EU to collaborate with the industry. The aim is to provide effective solutions that ensure an uninterrupted supply of medicines.

The Commissioner has announced that the Alliance will have access to a range of actions. These measures will involve public procurement, strategic partnerships to broaden global supply chains, boosting Europe’s production capacity for medicines and ingredients, and coordinating EU and national funding.

Lastly, the Commission will set up a network of international partners with the aim of addressing supply chain resilience. Kyriakides emphasised the importance of global collaboration in the quest to achieve greater variety in supply chains.

The pressing issue at hand is being addressed by the health minister of Spain, Jose Manuel Minones, who currently chairs the EU Council presidency. He expressed his approval of the Commission’s announcement during a meeting of the Parliament’s health and environment committee, which took place on October 23. There is a need to examine the supply chain for medicines and take proactive measures to ensure its robustness and efficiency, and they also aim to enhance the security of supply and assess the overall state of medicine availability beyond times of crisis.

Before the announcement by the Commission, Emer Cooke, the chief of the European Medicines Agency, presented to Parliament the actions being taken by the agency. As per her, they have successfully obtained the demand data from the member states as well as the supply information from the manufacturer. Furthermore, this has enabled to effectively identify areas where shortages or shortfalls may occur, allowing to take proactive measures in a timely manner. EMA has developed a regulatory toolkit to effectively manage critical shortages by closely tracking contact with manufacturers. Cooke pointed out the importance of exploring alternative suppliers and allowing certain labelling flexibility. The debate on shortages continues to be a topic of discussion.

Pharmaceutical marketing is the activity of promoting drugs and medical devices by private and public organizations to doctors, clinicians, and consumers. In 2022, approximately $603 billion dollars were spent on drugs in the United States, making marketing a top priority for major players in the pharmaceutical industry. Given this huge expenditure, most companies realize how important marketing is to gain pharma market access. In this article, we will look at the 4Ps concept and its application in pharmaceutical marketing.

Pharmaceutical marketing

Pharmaceutical marketing is the process of promoting prescription drugs and other medical products to both medical professionals (doctors, pharmacists and nurses), patients and consumers. Its primary goal is to increase product awareness, attract potential customers, and stimulate sales.

The pharmaceutical industry is governed by stringent government regulations aimed at safeguarding patients from inaccurate or deceptive assertions. These regulations exhibit variations across different nations and typically encompass areas such as:

• product claims must be truthful and supported by scientific evidence;
• many countries have restrictions on what types of statements can be made in product advertising;
• pharmaceutical companies are generally prohibited from giving gifts or payments to health professionals that could influence their prescribing decisions.

In addition to these regulatory challenges, pharmaceutical marketers also face a number of other challenges, including:

• product complexity – pharmaceutical products are complex and often have serious side effects that marketers must report;
• an oversaturated market;
• the cost of developing and marketing new pharmaceutical products is rising rapidly, putting pressure on marketers to be more effective in their campaigns.

Success in the pharmaceutical industry hinges on the imperative of strategic marketing. An effectively crafted marketing strategy has the potential to assist companies in achieving the following objectives:

• identify and target their target audience;
• position their products;
• increase brand awareness and trust in the company’s products.

By developing and implementing a strategic marketing plan, pharmaceutical companies can increase their chances of success in a highly competitive marketplace.

The 4Ps system in pharmaceutical marketing

Pharmaceutical marketing involves four key elements known as the 4Ps: product, price, distribution, and promotion. These four components work together to form a marketing strategy that helps pharmaceutical companies successfully introduce their products to the market.

Product

The Product aspect of the 4Ps framework considers the pharmaceutical product or service offered to the market. This aspect covers all the characteristics of the product including its physical properties, functional features and benefits to both patients and healthcare professionals.

There are many different types of pharmaceutical products, each with unique marketing characteristics. The most common types of pharmaceutical products include:

• prescription drugs;
• over-the-counter medications;
• vaccines;
• medical devices;
• generics (copies of brand-name drugs).

oping a marketing strategy for a pharmaceutical product, it is important to consider the specific needs and expectations of the target audience. For example, when promoting prescription drugs among medical professionals, it is necessary to emphasize the clinical effectiveness and safety of the drug. And when presenting over-the-counter drugs to consumers, it is important to emphasize their benefits and ease of use.

Price

The element “Price” within the 4Ps framework refers to the value that customers are willing to pay for a product. Price plays a key role in the marketing strategy of pharmaceutical products as it influences both the level of demand and the profitability of the product.

Pharmaceutical companies can utilize a number of different pricing strategies. Common pricing strategies include:

• cost-based pricing;
• value-based pricing;
• competition-based pricing.

When determining the price of a pharmaceutical product, companies must consider several factors including product development costs, the competitive environment, and the needs of both patients and healthcare providers.

The issue of affordabilits of serious importance in the pharmaceutical industry because many patients cannot afford to pay for the medications they need. Pharmaceutical companies are making efforts to address this problem by offering discounts and financial support programs to patients.

Place

The Place element of the 4Ps framework refers to the channels through which a pharmaceutical product is made available to customers. These channels include pharmacies, hospitals, and other health care facilities where the product can be purchased.

Distribution represents a critical aspect of pharmaceutical marketing because it ensures that patients and healthcare professionals have access to the products they need.

When choosing a distribution channel, pharmaceutical companies must consider a variety of factors, including product characteristics, target audience, and competitive environment. For example, drugs that require a prescription are most often distributed through wholesalers and pharmacies, while vaccines are often supplied through government agencies.

Promotion

The Promotion element of the 4Ps framework refers to the activities that pharmaceutical companies undertake to communicate the benefits of their products to target audiences. This includes various marketing methods such as advertising, public relations, sales promotion and direct marketing.

Pharmaceutical companies can utilize various advertising strategies. Some common advertising strategies include:

• advertising in various media, including television, radio, print, and the Internet;
• working with the media to create positive publicity for their products;
• promotions;
• direct marketing – pharmaceutical companies can contact patients and health care professionals directly through e-mail, direct mail and through sales representatives.

Pharmaceutical companies must adhere to strict rules and regulations that govern the promotion of their products, while also taking ethical considerations into account. For example, companies must avoid making claims about their products that may be misleading or lack scientific substantiation. This is important to ensure the safety and trust of patients and healthcare professionals.

Integrating the 4Ps into pharmaceutical marketing

The 4Ps system is a valuable tool for pharmaceutical marketers. A real-life example of how pharmaceutical companies successfully integrate the 4Ps is the case of AstraZeneca.

AstraZeneca is a global pharmaceutical company that specializes in the development, production and sale of a variety of prescription drugs and vaccines. The company’s marketing strategy focuses on informing healthcare professionals and patients about its products and services. In addition, AstraZeneca actively works to establish partnerships with key stakeholders such as government agencies and insurance companies.

AstraZeneca’s marketing mix is a combination of the 4Ps: product, price, place and promotion.

Product

AstraZeneca’s product portfolio includes a wide range of prescription drugs and vaccines, including those for the treatment of cancer, cardiovascular, respiratory and infectious diseases. The company also develops and markets biopharmaceuticals – drugs derived from living organisms.

Pricing

AstraZeneca’s pricing strategy is based on a number of factors, including the cost of developing and manufacturing a product, the competitive environment, and the needs of patients and payers. The company also offers patient support programs to help patients afford the drugs.

Location

AstraZeneca’s products are distributed through various channels, including wholesalers, pharmacies, and hospitals. The company also sells some of its products directly to patients.

Promotion

AstraZeneca promotes its products to healthcare professionals and patients through various channels, including advertising, public relations, sales promotion and direct marketing. The company also works with healthcare organizations to educate them about its products and services.

AstraZeneca’s marketing strategy is successful because it is well aligned – all four elements work together to achieve the company’s marketing goals.

This is just one example of how pharma companies can successfully integrate the 4Ps system to create effective marketing strategies. By carefully considering product, price, place and promotion of their products, pharmaceutical companies can reach their target audience and achieve their business goals.

Emerging trends in pharmaceutical marketing

The field of pharmaceutical marketing is constantly evolving, fueled by advances in technology and changes in the approach to patient care.

Digital marketing is playing an increasingly important role in pharmaceutical marketing. Pharmaceutical companies are utilizing digital channels to provide healthcare professionals and patients with information about their products and services. 

Digital marketing tactics include:

• search engine optimization (SEO);
• pay-per-click (PPC) advertising;
• social media marketing;
• content marketing.

Patient-centered approaches are also becoming increasingly important in pharmaceutical marketing. Pharmaceutical companies are shifting their focus from promoting products to engaging with patients. This means they are focusing on developing and marketing products and services that meet patient needs, as well as providing patients with information and support.

Data-driven strategies are also used to improve the effectiveness of pharmaceutical marketing campaigns. Pharmaceutical companies collect and analyze data from various sources such as patient surveys, sales data, and social media data. This data is used to better understand the needs of patients and healthcare providers and to develop more targeted and effective marketing campaigns.

Conclusion

This article has discussed the main aspects of the 4Ps of pharmaceutical marketing – product, price, distribution and promotion. It is important to note that a successful marketing strategy in the pharmaceutical industry requires not only the ability to promote products, but also high standards of ethics and responsibility, as pharmaceutical marketing has a huge responsibility for the health and well-being of patients.

Moreover, in the dynamic pharmaceutical industry, constant adaptation and innovation is encouraged. Striving to improve products and services, as well as finding new solutions to meet patient needs, should be at the center of marketing efforts. Only such companies will be able to remain competitive and contribute to the development of healthcare.